Halozyme Therapeutics Stock Price on November 12, 2024
| HALO Stock | USD 48.47 0.68 1.42% |
Below is the normalized historical share price chart for Halozyme Therapeutics extending back to March 12, 2004. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Halozyme Therapeutics stands at 48.47, as last reported on the 29th of November, with the highest price reaching 48.74 and the lowest price hitting 47.37 during the day.
If you're considering investing in Halozyme Stock, it is important to understand the factors that can impact its price. Halozyme Therapeutics holds Efficiency (Sharpe) Ratio of -0.0781, which attests that the entity had a -0.0781% return per unit of risk over the last 3 months. Halozyme Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Halozyme Therapeutics' Risk Adjusted Performance of (0.06), standard deviation of 3.76, and Market Risk Adjusted Performance of (0.22) to validate the risk estimate we provide.
As of the 29th of November 2024, Liabilities And Stockholders Equity is likely to grow to about 1.8 B, while Total Stockholder Equity is likely to drop about 66.9 M. . At this time, Halozyme Therapeutics' Price Earnings Ratio is very stable compared to the past year. As of the 29th of November 2024, Price To Operating Cash Flows Ratio is likely to grow to 13.18, while Price To Sales Ratio is likely to drop 5.59. Halozyme Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 16th of March 2004 | 200 Day MA 49.4841 | 50 Day MA 53.7228 | Beta 1.29 |
Halozyme |
Sharpe Ratio = -0.0781
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HALO |
Estimated Market Risk
| 3.8 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.3 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Halozyme Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Halozyme Therapeutics by adding Halozyme Therapeutics to a well-diversified portfolio.
Price Book 13.6219 | Enterprise Value Ebitda 12.0673 | Price Sales 6.5094 | Shares Float 125.9 M | Wall Street Target Price 62.4444 |
Related Headline
Agios Pharm Headline on 12th of November 2024
Agios Pharmaceuticals chief legal officer sells 1.14 million... by investing.com
Agios Pharmaceuticals chief legal officer sells 1.14 million in stock
Halozyme Therapeutics Valuation on November 12, 2024
It is possible to determine the worth of Halozyme Therapeutics on a given historical date. On November 12, 2024 Halozyme was worth 61.08 at the beginning of the trading date compared to the closed value of 59.61. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Halozyme Therapeutics stock. Still, in general, we apply an absolute valuation method to find Halozyme Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Halozyme Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Halozyme Therapeutics' related companies.
| Open | High | Low | Close | Volume | |
| 61.13 | 62.13 | 60.55 | 61.09 | 1,469,897 | |
11/12/2024 | 61.08 | 62.02 | 59.24 | 59.61 | 1,510,827 |
| 59.79 | 60.37 | 58.46 | 58.61 | 830,640 |
| Backtest Halozyme Therapeutics | | | Halozyme Therapeutics History | | | Halozyme Therapeutics Valuation | Previous | Next |
Halozyme Therapeutics Trading Date Momentum on November 12, 2024
| On November 13 2024 Halozyme Therapeutics was traded for 58.61 at the closing time. The top price for the day was 60.37 and the lowest listed price was 58.46 . The trading volume for the day was 830.6 K. The trading history from November 13, 2024 was a factor to the next trading day price decrease. The trading delta at closing time against the next closing price was 1.68% . The trading delta at closing time against the current closing price is 17.92% . |
Halozyme Therapeutics Fundamentals Correlations and Trends
By evaluating Halozyme Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Halozyme Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Halozyme financial account trend analysis is a perfect complement when working with valuation or volatility modules.About Halozyme Therapeutics Stock history
Halozyme Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Halozyme is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Halozyme Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Halozyme Therapeutics stock prices may prove useful in developing a viable investing in Halozyme Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 134.2 M | 104.7 M | |
| Net Income Applicable To Common Shares | 232.4 M | 244.1 M |
Halozyme Therapeutics Quarterly Net Working Capital |
|
Halozyme Therapeutics Stock Technical Analysis
Halozyme Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
Halozyme Therapeutics Period Price Range
Low | November 29, 2024
| High |
0.00 | 0.00 |
Halozyme Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
Halozyme Therapeutics November 29, 2024 Market Strength
Market strength indicators help investors to evaluate how Halozyme Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Halozyme Therapeutics shares will generate the highest return on investment. By undertsting and applying Halozyme Therapeutics stock market strength indicators, traders can identify Halozyme Therapeutics entry and exit signals to maximize returns
Halozyme Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Halozyme Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Halozyme Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Halozyme to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | (0.23) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.